Monday, June 26, 2017
QuintilesIMS to buy DrugDev
QuintilesIMS to buy DrugDev
As life science companies increasingly seek to gain insights from diverse data sources to make drug development more efficient and effective, Parexel International, a global biopharmaceutical services provider, is launching its Connected Journey of data-driven services. This newly integrated network, powered by PAREXEL Analytics capabilities, combines Parexel’s technology, processes and expertise to deliver critical intelligence supporting clinical development and commercialization.
Parexel International, a global biopharmaceutical services organization, announced a collaboration with Sanofi to advance the use of wearable devices to transform the collection of data in clinical trials.
Hassman Research Institute (HRI) announced that Dr. Larry Ereshefsky joined the company as chief scientific officer, Early Phase Development. Dr. Ereshefsky brings to HRI more than 40 years of drug discovery and development experience including leadership roles at University of Texas Health Science and Parexel. Dr. Ereshefsky will be responsible for leading HRI’s efforts and advancing the company’s Early Phase Development Division focusing on diseases. He will report to Dr. Howard Hassman, CSO of HRI.
Bridging the gap: Incorporating research into care
PSI, INC, Chiltern take top site ratings
INC Research Holdings, a global phase I to IV CRO, has appointed several new senior leaders to strengthen its Real World & Late Phase (RWLP) and Global Consulting offerings to biopharmaceutical customers worldwide. INC’s RWLP team is dedicated to real world, evidence-based data collection and works in close collaboration with the Company’s Global Consulting business to support customers at every stage of their product and portfolio development. INC’s expanded team will help maximize value for sponsors throughout the product lifecycle, from concept to commercialization, by providing consultative and operational expertise in the delivery of real-world evidence. The appointments reinforce INC’s continued focus on providing customers with strategic consulting services along with the right evidence to make the best clinical decisions in this rapidly expanding segment of the clinical research environment.
Parexel International, a global biopharmaceutical services provider, launched its patient sensor solution, a new offering that securely captures, transmits, stores and visualizes study subject data in clinical trials.
PAREXEL International, a global biopharmaceutical services organization, has been named to the FlexJobs Top 100 Companies to Watch for Telecommuting and Remote Jobs in 2017 list for the fourth consecutive year. The list recognizes companies that are telecommuting-friendly, allowing for candidates to telecommute on a full- or part-time basis.